TY - JOUR
T1 - Role of myeloid regulatory cells (MRCs) in maintaining tissue homeostasis and promoting tolerance in autoimmunity, inflammatory disease and transplantation
AU - Amodio, Giada
AU - Cichy, Joanna
AU - Conde, Patricia
AU - Matteoli, Gianluca
AU - Moreau, Aurélie
AU - Ochando, Jordi
AU - Oral, Barbaros H.
AU - Pekarova, Michaela
AU - Ryan, Elizabeth J.
AU - Roth, Johannes
AU - Sohrabi, Yahya
AU - Cuturi, Maria Cristina
AU - Gregori, Silvia
N1 - Publisher Copyright:
© 2018, The Author(s).
PY - 2019/4/2
Y1 - 2019/4/2
N2 - Myeloid cells play a pivotal role in regulating innate and adaptive immune responses. In inflammation, autoimmunity, and after transplantation, myeloid cells have contrasting roles: on the one hand they initiate the immune response, promoting activation and expansion of effector T-cells, and on the other, they counter-regulate inflammation, maintain tissue homeostasis, and promote tolerance. The latter activities are mediated by several myeloid cells including polymorphonuclear neutrophils, macrophages, myeloid-derived suppressor cells, and dendritic cells. Since these cells have been associated with immune suppression and tolerance, they will be further referred to as myeloid regulatory cells (MRCs). In recent years, MRCs have emerged as a therapeutic target or have been regarded as a potential cellular therapeutic product for tolerance induction. However, several open questions must be addressed to enable the therapeutic application of MRCs including: how do they function at the site of inflammation, how to best target these cells to modulate their activities, and how to isolate or to generate pure populations for adoptive cell therapies. In this review, we will give an overview of the current knowledge on MRCs in inflammation, autoimmunity, and transplantation. We will discuss current strategies to target MRCs and to exploit their tolerogenic potential as a cell-based therapy.
AB - Myeloid cells play a pivotal role in regulating innate and adaptive immune responses. In inflammation, autoimmunity, and after transplantation, myeloid cells have contrasting roles: on the one hand they initiate the immune response, promoting activation and expansion of effector T-cells, and on the other, they counter-regulate inflammation, maintain tissue homeostasis, and promote tolerance. The latter activities are mediated by several myeloid cells including polymorphonuclear neutrophils, macrophages, myeloid-derived suppressor cells, and dendritic cells. Since these cells have been associated with immune suppression and tolerance, they will be further referred to as myeloid regulatory cells (MRCs). In recent years, MRCs have emerged as a therapeutic target or have been regarded as a potential cellular therapeutic product for tolerance induction. However, several open questions must be addressed to enable the therapeutic application of MRCs including: how do they function at the site of inflammation, how to best target these cells to modulate their activities, and how to isolate or to generate pure populations for adoptive cell therapies. In this review, we will give an overview of the current knowledge on MRCs in inflammation, autoimmunity, and transplantation. We will discuss current strategies to target MRCs and to exploit their tolerogenic potential as a cell-based therapy.
KW - Dendritic cells
KW - Monocytes/macrophages
KW - Mye-EUNITER
KW - Myeloid regulatory cells (MRCs)
KW - Polymorphonuclear neutrophils
KW - Tolerance
UR - http://www.scopus.com/inward/record.url?scp=85055694134&partnerID=8YFLogxK
U2 - 10.1007/s00262-018-2264-3
DO - 10.1007/s00262-018-2264-3
M3 - Review article
C2 - 30357490
AN - SCOPUS:85055694134
SN - 0340-7004
VL - 68
SP - 661
EP - 672
JO - Cancer Immunology, Immunotherapy
JF - Cancer Immunology, Immunotherapy
IS - 4
ER -